PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.
-
Upload
joy-williamson -
Category
Documents
-
view
224 -
download
0
Transcript of PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.
![Page 1: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/1.jpg)
PATHOLOGY OF HYPOTHALAMIC-PITUITARY
AREA
As.-prof. Svystun I. I.
![Page 2: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/2.jpg)
The pituitary gland is the “master gland”, which lies in a bony structure, the sella turcica, located at the base of the skull. The gland is a small organ about I cm long; it weighs 500 mg and is divided into two parts, anterior (adenohypophysis) and posterior (neurohypophysis).
The anterior pituitary secretes- corticotropin (ACTH)- Prolactin- Somatotropin (growth hormone (GH)- gonadotropins [follicle-stimulating (FSH) and
luteinizing (LH) hormones]- thyrotropin (TSH)- melanocyte-stimulating hormones (MSH).In the nerve endings of the posterior pituitary are
stored - Vasopressin (antidiuretic hormone, ADH)- Oxytocin
![Page 3: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/3.jpg)
The hypothalamus plays an important role in hormone regulation by secreting a series of small peptides which stimulate or inhibit the synthesis and release of hormones by the anterior
pituitary• First hypothalamic releasing hormone identified in 1970 was TRH by Schalli and Guilemin who von Nobel prize in medicine for their discoveries in1977
• Realising Inhibiting- CRH - GIH (somatostatin)- TRH - PIF (dopamine)- GnRH- GHRH
![Page 4: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/4.jpg)
Regulation
![Page 5: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/5.jpg)
Etiology of hypothalamo – pituitary disorders
1. Tumor (craniopharyngiomas) or metastasis
2. Infectious diseases:- acute (scarlet fever, influenza)- chronic (tuberculosis, malaria, toxoplasmosis)
3. Trauma
4. Vascular damaging (thrombosis, thromboembolia)
5. Metabolic disorders (xanthomathosis)
6. Congenital pituitary hypo – or aplasia
7. Empty sella syndrome
7. Genetic predisposition
8. Idiopathic
![Page 6: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/6.jpg)
Manifestation of hypothalamo – pituitary disorders
• Hypersecretion (PRL, GH, ACTH)
• Hyposecretion (panhypopituitarism)
• Sellar enlargement (X-ray, CT, MRI)
• Visual loss (bitemporal hemianopsia or visual field defects)
![Page 7: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/7.jpg)
Pituitary tumors• Slow – growing (benign)• 10 – 15 % of all brain tumors:- Prolactinomas 60%- GH-secretion 20%- ACTH excess 10%
• Clinical presentations:1. Mass effect:- Headaches- Seizures- Facial pain or numbness- Apoplexia - Nausea, vomiting
![Page 8: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/8.jpg)
![Page 9: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/9.jpg)
![Page 10: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/10.jpg)
2. Visual loss (bitemporal hemianopsia or visual field defects)
3. Hormonal effects (overproduction or deficiency)
![Page 11: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/11.jpg)
Classification of hypothalamo – pituitary disorders
• Adenohypophysis disorders1. Secretion of GH- overproduction: acromegaly, giantism- dificiency: pituitary dwarfism2. Secretion of ACTH- overproduction: Cushing’s syndrome3. Secretion of Prolactin- overproduction: hyperprolactinemia, galactorhea-amenorhea4. Secretion of TSH - thyrotoxicosis5. Secretion of Gonadotropines: adiposogenital-dystrophy6. Hypopituitarism7. Hypothalamic obesity• Neurohypophysis disorders1. Dificiency of vasopresin: diabetes insipidus2. Inapropritiative secretion of vasopresin
![Page 12: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/12.jpg)
GROWTH-HORMONE EXCESS(acromegaly and gigantism)
Chronic disorder resulting from excessive secretion of GH and resulting in production of insulin-like growth factor 1 (IGF-1), which lead to typical picture: gigantism before puberty and to acromegaly after puberty
![Page 13: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/13.jpg)
Etiology1. Adenoma (acidophilic or chromophobe) of
the pituitary2. Ectopic GH-producing tumors (cancer of
lungs, mamma glands, pancreatic gland)3. Regulatory hypothalamus disturbances
(overproduction of somatoliberin or deficiency of somatostatin)
4. Ectopic GRH-producing tumors (carcinoid tumor of intestine,lungs)
![Page 14: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/14.jpg)
Clinical manifestations of gigantism• Mass effects• Overproduction of GH- height more than 190 cm in
women and 200 cm in men- Hypersecretion of GH prior to
closure of epiphysis leads to proportional growth of bone; both length and width of bone are increased
- May be blood hypertension, myocardiodystrophy, atrial fibrillation
![Page 15: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/15.jpg)
• Leonid Stadnyk - 7 feet 7 inches (231.1 cm) with Yushchenko V. (president of Ukraine 2005-2010), 183 sm.
![Page 16: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/16.jpg)
Acromegaly - Named “acromegaly” by
Pierre Marie in 1886 from Greek akron (extremities) and megas (large)
- Rare condition- 3 – 4 new cases per million
population per year- Affects both sexes equally- Peak ages 40 – 60 years- Mortality 10 times higher
than in control group mostly due to cardiovascular disorders
![Page 17: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/17.jpg)
Clinical manifestations of acromegaly
• Syndromes connected with influence of GH on organs and tissues:
1) periostal overgrowth:- overgrowth of the
mandible leads to protrusion of the jaw (prognatism)
- there ia an overbite and the teeth become separated (diastema).
![Page 18: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/18.jpg)
2) cortical thickening(characteristic coarsening of the facial features)
![Page 19: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/19.jpg)
3) Hypertrophy of soft tissues of hands and feet (the hands are widened and the fingers become broad, requiring a larger ring size. Similar changes in the feet require a larger shoe size)4) arthropathy, carpal tunnel syndrome 5) Hypertrophy of tongue, sleep apnoe
6) The skin is thickened, andfemales may note hypertrichosis, excessive sweating
![Page 20: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/20.jpg)
II. Changes from the inner organs:- Hepatomegaly and cardiomegaly- Hypertension is present in 40 % of patients - The kidney may also become enlarged, and renal clearance of
phosphate is frequently impaire
III. Syndrome of reproductive disturbances:- Amenorrhea, which occurs in as many as two-thirds of female
patients, may be the chief complaint. Decreased libido, impotention is experienced by one-third of the patients (due to prolactin – like effects of GH)
IV. Syndrome of endocrine disorder- thyromegaly is present in about 25 % of the patients (hyper-
and hypothyroidism occurs rarely) - the abnormalities in glucose metabolism (diabetes mellitus)- hyperfunction or deficiency of other pituitary trophic hormones
V. Mass effects (headaches, vision field disorders)
![Page 21: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/21.jpg)
Diagnosis of acromegaly is usually suspected from:
1. The patient's history
2. Physical examination
3. Laboratory investigations:- The level of GH (0,5 – 5,0 ng/ml)- IGF-1- Test with glucose suppression of
growth-hormone secretion- Test with TRH
![Page 22: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/22.jpg)
• Value of old pictures
![Page 23: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/23.jpg)
3. Enlargement of the sella turcica (90 % of patients) X-ray, CT,MRT
4. Visual - field defects (bitemporal hemianopsia)
![Page 24: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/24.jpg)
Differential diagnosis• Gigantism
- constitutional high height
- Klainfelter’s syndrome
- Marphan syndrome• Acromegaly
- hypothyroidism
- Peget’s syndrome
![Page 25: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/25.jpg)
Pharmacologic therapy1. A dopaminergic agonist and ergotamine derivative, 2a-
bromergocriptine (bromocriptine 10 to 60 mg/day, (clinical remissions in 73 % patients, normalization of GH level in 22 % of patients).
Side effects include nausea, orthostatic hypotension, consti pation, digital vasospasm, and peptic ulcer.
2. Comatostatin analogues: octreotide, sandostatin (clinical remissions in 90 % patients, normalization of GH level in 50 % of patients).
Side effects include nausea, diarrhea, gallstones, glucose intolorence.
3. SOMAVERT (pegvisomant for injection) is a prescription medicine for acromegaly. It is for patients whose disease has not been controlled by surgery, radiation, and/or other medical therapies, or patients for whom these options are not appropriate. The goal of treatment with SOMAVERT is to have a normal IGF-I level in the blood.
![Page 26: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/26.jpg)
Treatment Surgery: - Transsphenoidal hypophysectomy is the procedure of
choice. Advantages: effectivity in nearly 90 % of the patients, simplicity
and low morbidity. Side effects: hypopituitarism, diabetes insipidus, recurrence of symptoms.- Craniotomy is reserved for large tumors with
suprasellar extension and involvement of the optic chiasm.
- Cryohypophysectomy (destruction of the pituitary by cold injury) can reduce the secretion of GH (without causing hypopituitarism) in 88 % of the patients.
External irradiation:- External beam- Gamma knife
![Page 27: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/27.jpg)
PITUITARY DWARFISM (GROWTH FAILURE) -
it is the disease caused by decreased secretion of GH by pituiatary gland or decreased sensitivity of peripheral tissues to this hormone and leads to growth retardation.
Epidemiology- 3 – 4 new cases per 1million
population per year
- affects both sexes equally
![Page 28: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/28.jpg)
Etiology• Congenital deficiency of GH- Genetic disorders - Defect of pituitary gland development (aplasia, hypoplasia)
• Acquired deficiency of GH- trauma, neoplasms (craniopharyngioma), infection
• Peripheral resistance for GH- Pathology of GH receptors (Laron’s syndrome)- Biologically inactive GH
No demonstratable etiology (idiopathic hypopituitarism) (The latter is more frequent in males than in females)
![Page 29: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/29.jpg)
Classification
A. Organic (trauma, neoplasms, infection).
B. Idiopatic (primary or secondary, due to hypothalamic deficiency).
1. Panhypopituitarism.
2. Isolated GH deficiency (may be hereditary and transmitted as an autosomal recessive trait, in other instances a hereditary basis cannot be established).
![Page 30: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/30.jpg)
Clinical manifestations. The height of adult men is less than 130 cm,
and adult women is less than 120 cm.
1. Child is born with normal weight and height.2. Growth retardation can be observed since 3 – 4
years (the increasing of the height is not more than 1 cm per year).
3. The patient, despite small size, has normal body proportions.
4. Mental develoment is normal.5. Secondary hypothyroidism.6. Secondary adrenal insufficiency.7. Puberty will not appear because of a lack of
gonadotropic hormons (secondary hypogonadism).8. The passport age is not corresponding with biologic
age.9. In patients with isolated GH deficiency the patients
have normal pituitary function (other than lack og GH), undergo normal puberty, and have normal reproductive capacity
![Page 31: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/31.jpg)
Jyoti Amge's, 15 y.o.,born December 16, 1993a resident of Nagpur, India
![Page 32: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/32.jpg)
• Born Karl Kosiczky on September 21 1918 in Prakendorf, Hungary (now in Slovakia), he stopped growing at the age of four and was diagnosed with pituitary dwarfism. Karl Slover, who has died aged 93, was a member of the "Singer Midgets" vaudeville troupe and played several roles as a Munchkin in the 1939 film classic The Wizard of Oz.
![Page 33: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/33.jpg)
Premordial dwarfism1. Child is born with decreased weight and height
(1000-1200 g); 2. Growth retardation can be observed from
earliest infancy3. Sexual development occur normally or at only a
slightly retarded rate 4. Bones abnormalities5. Mental retardation
![Page 34: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/34.jpg)
![Page 35: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/35.jpg)
Diagnosis
Clinical picture (carefully recorded growth charts may disclose the time of onset of the disease)
level of GH, IGF-1
X-ray examination of the skull and hands
Fields of vision
Before the diagnosis of pituitary dwarfism can be made, all other etiologies must be ruled out
![Page 36: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/36.jpg)
Differential diagnosis – hypothyroid dwarfism
- chondrodystrophy- progeria (syndrome of Getchison -
Vilford). - Villi - Prader syndrome
- Terner syndrome - somatogenic dwarfism
- Constitutional (normal variant) short stature.
- Psychosocial dwarfism .
![Page 37: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/37.jpg)
Treatment.I. Balanced diet.II. Complex of physical exercises.III. Pharmacotherapy.1. GH (synthetic). Indications: a low level of GH or a low level of
somatomedin in patients with biologic age less than 12 – 13 years and passport age more than 3 years. Doses of 2 – 4 IU of GH given IM at night time three times a week for 2 – 3 months with 2 – 3 months break have accelerated the rate of linear growth, through often this therapeutic effect is not sustained.
2. Anabolic steroids under the control of biologic (osteal) age.3. Thyroid replacement.4. Replacement with gonodal steroids is never indicated until
puberty normally occurs. These agents in high doses can hasten bone maturation and epiphyseal closure, thereby limiting the height which may ultimately be reached.
5. Vitamin therapy.IV. Surgical therapy (a craniopharyngioma presents special
therapeutic problems, usually necessitating removal of tumor tissue or drainage of fluid from tumor cysts.
![Page 38: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/38.jpg)
HYPOPITUITARISM
It is the syndrome, which is characterized by deficiency of one or more anterior pituitary hormones.
Epidemiology
- affects mostly women at age 20 - 40
![Page 39: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/39.jpg)
EtiologyPrimary:- pityitary aplasia, hypoplasia, - tumors (chromophobe adenomas, craniopharyngiomas,
pituitary cysts) - postpartum uterine hemorrhage (Sheehan's syndrome)- autoimmune and infiltrative (hemochromatosis,
sarcoidosis) processes- Infectious (tuberculosis, fungi)- pituitary irradiation or surgery- traumatic or surgical destruction of the hypothalamic-
pituitary areaSecondary:• Hypothalamic disorders
![Page 40: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/40.jpg)
Classification
• Total or panhypopituitarism
• Partial hypopituitarism with isolated deficiency of one or two hormones
![Page 41: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/41.jpg)
The symptoms of hypopituitarism mimic those of many diseases.
Watch for pituitary insufficiency: 1. In women who fail to lactate following pregnancy and
delivery. (Involution of breasts and sparse axillary and pubic hair would suggest the diagnosis.)
2. In females with unexplained amenorrhea, particularly if symptoms of ACTH and TSH deficiency or increased intracranial pressure are present.
3. In males with decreased libido and loss of axillary and pubic hair.
4. In patients with unexplained anemia. 5. In diabetic patients who experience a reduction in
insulin requirements.)
![Page 42: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/42.jpg)
Clinical manifestationsClinical symptoms are
not present unless 75 % of the gland is destroyed.
1) Hypogonadism (early symptom)
2) Hypothyroidism3) Hypocorticism4) In children:
drowth retardation; in adult weakness, muscle atrophy, kachexia
5) Neuro – psychiatric changes, hypothalamic disorders (vegetative crises, termoregulation disorders)
6) Mass effects
![Page 43: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/43.jpg)
Diagnosis 1. Physical examination 2. Laboratory findings• anemia, hypercholesterolemia, tendency to
hypoglycemia• hormonal assessment (decreased levels of pituitary
and peripheral endocrine glands)
3. Instrumental investigations• X-ray of cella turcica (the upper limits of normal for sellar
dimensions are length 17mm, depth 13mm, and width 15mm )• CT,MRI
• Cerebral angiography• Ophthalmologist (fields of vision, retina)
![Page 44: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/44.jpg)
Differential diagnosis
• Anorrhexiaa nevrosa• Shien syndrome• Primary hypothyroidism• Shmidt syndrome (peripheral
autoimmune poliendocrine deficiency)
• Malignant tumors, tuberculosis, enterocolitis
![Page 45: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/45.jpg)
Treatment - eliminating the underlying cause - replacing the deficient hormones
- Pituitary tumors should be removed surgically, although irradiation and drug therapy (bromocriptine) are also available.
- Treatment of acute and chronic infection Hypothalamic peptides or pituitary hormones are not suitable for
hormone replacement : (1) The human hormones are difficult to obtain in pure form; (2) because of their nature and short half-life they have to be given i.v. and frequently; (3) since they stimulate antibody formation, their activity is lost a few weeks after initiation of therapy.
Under these circumstances the usual practice is to administer the hormones produced by the target glands. They are available in pure form and are relatively inexpensive.
![Page 46: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/46.jpg)
Replacement therapy
• Hydrocortisone 20 - 30 mg/day, prednisolone 5 - 15 mg/day
• Replacement with gonodal steroids is never indicated until puberty normally occurs. These agents in high doses can fasten bone maturation and epiphyseal closure, thereby limiting the height which may ultimately be reached.
- In males testosterone therapy is recommended. - Premenopausal females with ovarian failure should
be treated with estrogens.• Thyroid drugs (L-thyroxin)• Vitamins, anabolic hormones
![Page 47: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/47.jpg)
DIABETES INSIPIDUS
is a clinical disorder characterized by
the excretion of large quantities of diluted urine
and caused either by failure of ADH release (hypothalamic diabetes insipidus) or by
lack of response of the tubules to normal quantities of circulating ADH (nephrogenic diabetes insipidus).
![Page 48: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/48.jpg)
Etiology. Causes of hypothalamic diabetes insipidus:1. Surgery2. Trauma 3. Tumors (craniopharyngioma) or metastatic (carcinoma of
the breast).4. Infiltration of the hypothalamus by leukemic cells,
granuloma (sarcoidosis, tuberculosis), histiocytes (Hand-Schuller-Christian disease), or infections.
5. Idiopathic.6. Familial.
Causes of nephrogenic diabetes insipidus1. Hereditary factors: X-linked transmission with predominance
in males.2. Acquired factors (Drugs: Lithium carbonate, demeclocycline.
methoxyflurane and amphotericin, renal diseases)
![Page 49: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/49.jpg)
Clinical picture
1. The hallmark of diabetes insipidus is the excretion of large quantities of urine (usually 5 to 10 L/day, but the amount can be more). In mild forms of diabetes insipidus, polyuria may be minimal with urine volumes of 2 to 4 L/day.
2. Polydipsia (ingesting of large amounts of mostly cold water).
3. Insomnia, decreasing of appetite, dryness of skin and mucous membranes, pharyngitis, gastritis, constipation are common in patients.
4. In situations in which the patient has no access to water, is unconscious, or has an abnormality of the thirst mechanism, severe dehydration may ensue.
![Page 50: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/50.jpg)
Diagnosis
1. The patient's history
2. Physical examination
3. Laboratory signs:- a specific gravity of urine less than 1,005 - an osmolality of less than 100 mosmol/kg- serum osmolality is increased. - level of ADH can be decreased
4. Instrumental, neurological, ophthalmoscopic examination
![Page 51: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/51.jpg)
Psychogenic polydipsia
Hypothalamic diabetes insipidus
Nephrogenicdiabetes insipidus
History Insidious onset Abrupt onset, brain surgery, tumor present, steroid therapy
Family history, chronic hypokalemia, chronic hypercalcemia, postanesthesia
Physical examination
Normal hydration Dehydration may be present
Dehydration may be present
Laboratory:- serum osmolality;- urine osmolality
270 – 290 (↓ to N)< 200 (↓)
285 – 320 (N to ↑)< 200 (↓)
285 – 320 (N to ↑)< 200 (↓)
Adiuretin administration
Patient feels ill; no change in serum osmolality; increase in urine osmolality
Patient feels better; decrease in serum osmolality; increase in urine osmolality
No change in serum or urine osmolality
![Page 52: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/52.jpg)
Treatment• Etiologic• Pathogenetic- Hypothalamic DI- Adiurecrin powder nasal spray0,03 g 1 – 3 times a day- Adiuretin in drops 1 – 3 times a day- Synthetic lysine vasopressin, desmopressin 1 to 2 sprays three
or four times a day.- Pituitrin 0,5 – 1 ml subcutaneous 2 – 3 times a day.
- Nephrogenic DI- chlorpropamide 100 to 500 mg/day- Tegretol (400 mg/day)- diuretics (thiazide diuretic (50 to 100 mg/day of
hydrochlorothiazide) is added to enhance the sodium depletion and impair the ability of the tubules to generate a dilute urine)
![Page 53: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/53.jpg)
THE SYNDROME OF INAPPROPRIATE SECRETION OF ADH
is characterized by persistent ADH secretion and the excretion of a concentrated urine despite serum hypoosmolality.
![Page 54: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/54.jpg)
Diagnostic criteria The characteristic features of the syndrome include:1. Hyponatremia.2. Serum hypoosmolality.3. Continuous urinary sodium excretion despite hyponatremia.4. Urine osmolalily usually greater than the serum osmolality.5. Absence of clinical edema.6. Reversal of the abnormalities following water restriction.7. Symptoms are usually not present unless the serum sodium
concentration falls below 120 meq/L. When this occurs, headaches, anorexia, nausea, and vomiting may ensue. With marked hyponatremia (100 to 110 meq/L), symptoms related to the central nervous system, such as confusion, disorientation, hostility, convulsions, and coma, may predominate. Arrhythmia may also occur.
![Page 55: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/55.jpg)
Differential diagnosis
It is recommended that cardiac, hepatic, adrenal, and renal disease be ruled out before making the diagnosis of inappropriate ADH secretion.
The differential diagnosis of the syndrome of inappropriate ADH secretion is that
of dilutional hyponatremia.
![Page 56: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/56.jpg)
Treatment1. Identification of the underlying cause and measures to correct
it are important therapeutic goals.2. The mainstay of therapy for the syndrome of inappropriate
ADH secretion is water restriction to less than 1 L/day. Weight loss and an increase in serum sodium concentration will occur 3 to 7 days after therapy has been started.
3. In patients who present with marked hyponatremia (less than 110 meq/L) and neurologic symptoms, particularly seizures, infusion of 250 ml of hypertonic saline (3 % NaCI) over 2 to 4 h is indicated.
4. Furosemide in combination with intravenous or oral sodium chloride sometimes is effective. The therapeutic goal is to increase free water clearance and at the same time to replace the sodium urinary losses .
![Page 57: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/57.jpg)
HyperprolactinemiaDifferential diagnosis of hyperprolactinemia
depends on the prolactin level
• >250 ng/ml (>5000 mU/l) is diagnostic of prolactin – secreting adenoma (exept for pregnancy)
• <250 ng/ml may be due:- Adenoma- Drugs (verapamil, cimetidine,
esrogens, opiates, reserpine, α-metyldopa; halaperidol, metoclopramide)
- Severe primary hypothyroidism- Interruption of pituitary stalk by
tumor or other infiltrative diseases
![Page 58: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/58.jpg)
Clinical manifestations of hyperprolactinemia
• Hypogonadism in both women and men by supressing GnRH secretion and pulsutility, resulting in low levels of LH and FSH
![Page 59: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/59.jpg)
Treatment of Hyperprolactinemia• Pharmacologic
1.Dopamine agonists are the first line treatments: bromcriptin- Inroduced in Europe in 1970’s- Stimulates D2 receptors on lactotroph inhibiting prolactin
synthesis and release- Side effects: nausea, dizziness, hypotension, nasal stuffiness
2. Other agents:
1) Pergolide 2) Carbegoline (long half life)
![Page 60: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/60.jpg)
Treatment of Hyperprolactinemia
• Surgery cures (< 20% of large tumors
- Transphenoidal - Frontal cranitomy• Radiation therapy• Radiotherapy (gamma
knife)
![Page 61: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/61.jpg)
Obesity
![Page 62: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/62.jpg)
Epidemiology• Nearly 30 % of world population suffers from
different stages of obesity
• Its importance lies in the many, often serious, complications to which obese people are subject. In these complications that warrant undertaking a treatment that is so often unsuccessful
![Page 63: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/63.jpg)
Health consequences• Diabetes mellitus• Hypertension• Coronary artery disease• Obstructive sleep apnea• Certain malignancies• Cholelithiasis
(gallbladder disease)• Arthritis• Infertility
![Page 64: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/64.jpg)
OBESITY
is a state of increased body weight, specifically fat, of sufficient magnitude to exert adverse effects on health
(Obesity is characterized by excessive accumulation of body fat)
![Page 65: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/65.jpg)
Etiology
The cause of obesity is simple – consuming more calories than are expended as energy.
Why patients become obese?
Why persons consume more calories than they expend?
![Page 66: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/66.jpg)
Predisposing factors• “Obesogenic” environment:
social,
cultural,
behavioral factors
- Excess of calorie
intake
- Sedentary
lifestyle
![Page 67: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/67.jpg)
Predisposing factors• Sex• Endocrine factors. (Certain diseases of endocrine
glands are associated with obesity i.e. hypothyroidism, Cushing’s disease, hypogonadism.)
• Psychological factor• Brain (especially, hypothalamic injury)• Genetic factors (It is widely recognized that obesity
runs in families: 80 % of the offspring of 2 obese parents are obese, compared with 40 % of the children of 1 obese parent and only 10 % of the offsprings of 2 nonobese parents)
![Page 68: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/68.jpg)
Classification by Egorov
1. Alimentary
2. Endocrine
3. Cerebral (hypothalamic)
![Page 69: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/69.jpg)
Classification due to stages of
obesity
A. Brock’s index
(N: weight = height – 100)
I. Weight excess < 30 %.
II. Weight excess 30 – 50 %.
III. Weight excess 50 – 100 %.
IV. Weight excess > 100 %.
B. Kettle’s index
BMI (body mass index)
(N: weight, kg / height, m2)
Overweight: 25,1 – 29,9
I. 30,0 – 34,9
II. 35,0 – 39,9
III. > 40,0
![Page 70: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/70.jpg)
Body mass index
Weig
ht (kg
)
obesity overweight normal low weightprominentobesity
Height (sm)
![Page 71: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/71.jpg)
Limitations of BMI• Can overestimate
body fat in muscular individuals
• Can underestimate body fat in those who have lost muscles (elderly, sedimentary)
• Does not describe distribution of body fat
![Page 72: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/72.jpg)
Classification due to deposition of fat tissue• upper type (abdominal, android);• lower type (gluteofemoralis, gynoid).
![Page 73: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/73.jpg)
Abdominal obesity
• Waist/hip ration
- >1,0 in men
- > 0.85 in women• Waist circumference
- >90 (102 )cm in men
- > 80 - 82 cm in women
• Both methods identify those with increased CVD risk
![Page 74: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/74.jpg)
Visceral fat is metabolically active
• Cytokines:- TNF – alfa- Interleukin - 6• “Adipokines”- Resistin- Adiponectin • Prothrombotic
mediators: PAI-1
![Page 75: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/75.jpg)
Pathogenesis: imbalance between energy supply and demand
• Insulin plays a major role in regulating of food intake• When you eat too much you will end with insulin resistance
![Page 76: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/76.jpg)
Body weight regulation
• Enzymes, metabolic defects of peripheral receptors• Imbalance on the hypothalamus level• Endocrine system disorders• Defects of sympathetic regulation
![Page 77: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/77.jpg)
Clinical manifestations
• Obese people come to the doctor not only complain about their fitness but also with complications:
- cardiovascular- pulmonary- orthopedic and others
![Page 78: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/78.jpg)
![Page 79: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/79.jpg)
Alimentary obesity
1. Genetic (family) factor.
2. Eating habits (ingestion of large amounts of food).
3. Slow progressing
![Page 80: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/80.jpg)
Hypothalamic obesity
1. Fast gain weight (20 – 30 kg during 1 – 2 years).
2. More frequent dysplastic localization of the fat.
3. The presence of the striae.
4. Symptoms associated with increased intracranial pressure and neurologic picture (somnolence, raised appetite and others).
5. Signs of hypothalamic dysfunction (palpitation, hyperhydrosis, hypertension).
![Page 81: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/81.jpg)
Pickwickian syndrome
It can occur in the massively obese persons.
Pressure on the thorax from the encompassing sheath of the fatty tissue combined with pressure on the diaphragm from below by large intra-abdominal accumulations may lead to reducing of the respiratory capacity, hypoventilation, retention of CO2 leading to decreased effects of CO2 as respiratory stimulant and resultant hypoxia and somnolence.
![Page 82: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/82.jpg)
Barraquer–Simons syndrome(progressing lipodystrophia)
1. More frequent is in young women.
2. Atrophy of the subcutaneous adipose tissue in the region of face neck, thorax; increased quantity of adipose tissue in the lower part of body, thighs, legs (“riding-breeches” type).
3. Duration of the disease, as a rule, without any changes in nervous and endocrine system and patients have only cosmetic defect.
![Page 83: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/83.jpg)
Dercum disease (generalized painful lipomatosis)
1. More frequent is in women in menopause.
2. There is localized, painful nodes (knots) in the subcutaneous adipose tissue. These nodes are painful, itch, the skin over nodes is red.
3. Patient can have normal weight or be obese.
4. Person has nervous changes (CNS asthenia, neuroses) and endocrine disturbances (decreasing of function of sexual glands).
![Page 84: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/84.jpg)
Babinski-Fröhlich syndrome(adipose-genital dystrophy)
1. More frequently is observed in boys.
2. Characterized by obesity (dysplastic type) and hypogenitalism (development of primary and secondary sexual signs is stopped: small sizes of scrotum, penis, may be criptorchism).
3. There is often lack in growth.
![Page 85: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/85.jpg)
Laurence-Moon-Biedl syndrome or Laurence-Moon-Biedl-
Bardet
1. Obesity, hypogenitalism like in patients with Babinsky-Frelych’s disease.
2. Decreased mental activity or debility.
3. Pigmental retinitis.
4. Bones or inner organs abnormalities (polydactylia, syndactylia and others)
http://www.primehealthchannel.com
![Page 86: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/86.jpg)
geneticdisease2.wikispaces.com
Bardet–Biedl Syndrome
![Page 87: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/87.jpg)
Morgagni Stewart Morel syndrome
1. More frequent in young women or in climacteric female.
2. Adipose tissue localized in the region of chin, abdomen (like apron) mammary glands (mastoptosis), skin is flabby, striae are absent.
3. Hirsutism is present (beard, moustache).
4. Hypertension.
5. Diabetes mellitus.
6. Increased thickness of lamina interna of frontal bone.
www.lookfordiagnosis.com
![Page 88: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/88.jpg)
Polycystic ovary syndrome
- Obesity - Dysmenorrhea - Infertility - Hypoplasia of uterine- Signs of virilization (beard,
moustache) - Mammary glands are served- Signs of musculanization
![Page 89: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/89.jpg)
TreatmentThe prognosis for obesity is poor, particularly for obese
children, and the course tends to progress throughout the life.
Obesity is a chronic condition resistant to treatment and prone to relapse.
Most obese persons will not participate in outpatient treatment, and those who do will not lose a significant amount of weight.
Most of those who do lose weight will regain it. These results are poor, not because of failure to
implement any therapy of known effectiveness, but because no simple or generally effective therapy exists.
The basis of weight reduction in all treatment regimens is to establish a caloric deficit by reducing intake below output
![Page 90: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/90.jpg)
Diet
The simplest way to reduce caloric intake is with a low-calorie diet.
Optimal long-term effects are achieved with a balanced diet containing readily available foods.
For most people, the best reducing diet consists of their usual foods in amounts limited with the aid of standard tables of food values.
Such a diet gives the best chance of long-term maintenance of the weight loss, although it is the most difficult diet to follow during weight reduction
![Page 91: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/91.jpg)
Several recommendationsPatient has to:
1. eat 4 – 5 times a day, only in a direct time, not to eat between basic meal receptions;
2. eat only one portion;
3. limit a free liquid to 1,0 – 1,2 l/day;
4. not to eat with the aim of decreasing depression, not to eat “for a company”;
5. the total daily energy intake should be between 1600 – 800 Kcal.
![Page 92: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/92.jpg)
Physical activitymost important for maintance of weight
loss
Physical activity has to be:
1) Regular (30 – 45 – 60 min walking/day 7 days/week)
2) Bring only positive emotions
3) Group support
4) Any exercise is better than no exercise (bike, walk, dance)
![Page 93: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/93.jpg)
Pharmacotherapyhave to be combined with diet and lifestyle changes
• Drugs that have weight loss as “side effect” – metformine
• Many preparations (amphetamines, phenterminefenfluramine, others) are used as anorectic drugs. But, weight is regained after drug treatment. Side effects: raises BP and pulse, pulmonary HTS
• Meridia (sibutramine) was withdrawn from the U.S. market in October 2010.
• Orlistate (Xenical) (Investigation EXPERT) decreases fat absorption and inhibits pancreatic lipase. Side effects: oily stool, flatulence, vitamine A,D,E,K malabsorption
![Page 94: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/94.jpg)
• Belviq (lorcaserin) affects chemicals in the brain that affect appetite (Belviq work by turning on a specific chemical “switch” in the brain that increases levels of serotonin)
• Belviq is used together with diet and exercise to treat obesity• Belviq is sometimes used to treat obesity that may be related to diabetes,
high cholesterol, or high blood pressure.• Aim-lose at least 5% of starting weight after taking the medication for 12
weeks.• People taking Belviq had an average weight loss that was 3 to 3.7
percent greater than people taking placebo.• After taking Belviq for one or two years, some 47 percent of people
without diabetes lost at least 5% of their body weight (only 23 percent of patients taking an inactive placebo lost this much weight.)
![Page 95: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/95.jpg)
• Qsymia combines two generic drugs in a new formulation. One half the drug is composed of the seizure and migraine medication called topiramate. Topiramate causes weight loss in several ways, including increasing feelings of fullness, making foods taste less appealing, and increasing calorie burning. The other half of Qsymia is the appetite-suppressant called phentermine. Phentermine is thought to suppress appetite by triggering release of a brain chemical that increases blood concentrations of the appetite-regulating hormone leptin.
![Page 96: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/96.jpg)
• People taking Qsymia for up to one year had an average weight loss of nearly 9 percent over those taking an inactive placebo. Over 70 percent of people taking Qsymia lost at least 5 percent of their body weight (only 20 percent of patients taking an inactive placebo lost this much weight).
![Page 97: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/97.jpg)
Surgery Radical surgical treatment may offer some
hope to persons with morbid obesity (100 % overweight) in whom all others treatments have failed
Roux-en-Y stomach surgery for weight loss
![Page 98: PATHOLOGY OF HYPOTHALAMIC-PITUITARY AREA As.-prof. Svystun I. I.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649de45503460f94adb9e2/html5/thumbnails/98.jpg)
Adjustable gastric banding